ArticleMolecular biology reports2026
Cytotoxic and molecular effects of S-allylcysteine on uterine leiomyoma primary culture cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine leiomyomas (fibroids) are the third most common, hormone-dependent benign tumors characterized by abnormal cell proliferation and dysregulation of signalling pathways, particularly PI3K/AKT. S-Allylcysteine (SAC), a bioactive compound from aged garlic (Allium sativum), possesses anti-inflammatory and anticancer properties, but its effects on leiomyoma cells remain poorly understood.
aimThis study aimed to evaluate the cytotoxic effects of SAC on primary uterine leiomyoma culture cells and its molecular influence on PI3K/AKT pathway-related gene expression.
methodsA total of 25 uterine leiomyoma and 10 adjacent apparently normal myometrium paired tissues were collected from women with uterine leiomyoma. Of the 25 patients included for primary cell culture study, paired leiomyoma and adjacent myometrial tissues were obtained from 10 patients, while leiomyoma tissues alone were obtained from the remaining 15 patients. Primary uterine leiomyoma and adjacent myometrial cells were cultured in DMEM/F12 medium and treated with SAC (12.5-400 µg/ml) for 48 h. Cell viability was assessed by MTT assay, morphological changes were examined microscopically, and expression of PI3K (specifically PIK3R1), AKT3, MTOR, and PTEN was analysed by RT-qPCR using GAPDH as the housekeeping gene. Relative expression was calculated by the ΔΔCt method. Statistical analysis was performed using a one-way repeated-measures ANOVA test.
resultsSAC significantly reduced ULPC viability in a dose-dependent manner, with an IC₅₀ of 255.71 ± 17.12 µg/ml (p < 0.05). Treated cells showed apoptotic features, including cell rounding, shrinkage, and reduced confluency. UMPC cells exhibited lower sensitivity, indicating a differential cytotoxicity response. SAC significantly downregulated transcript levels of PI3K, AKT3, and MTOR, while upregulating PTEN (p < 0.05).
conclusionThese findings indicate that SAC exerts selective cytotoxic effects on uterine leiomyoma cells, likely through modulation of the expression of selected PI3K/AKT pathway-related genes, supporting its potential as a therapeutic agent for uterine leiomyoma.
Indexed as
Identifiers
42690532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.